TACE combines local chemotherapy with arterial embolization
Charité describes TACE as treatment of highly vascularized liver tumors by advancing a microcatheter into tumor-feeding hepatic arteries, delivering chemotherapy locally and then embolizing the arterial supply. This increases local drug exposure while reducing blood flow to the treated tumor territory.
Patient selection is more important than the catheter technique
TACE should not be treated as an automatic next step after an HCC diagnosis. Current HCC guidance emphasizes individualized multidisciplinary planning and transitions between surgery, transplantation, ablation, transarterial treatment, radiation and systemic therapy.
- Primary diagnosis and pathology when available
- Number, size and distribution of liver tumors
- Whether disease is confined to the liver or extrahepatic
- Baseline liver function and degree of cirrhosis
- Portal vein patency and hepatic vascular anatomy
- Previous surgery, ablation, TACE, SIRT or radiation
- Current or planned systemic treatment
- Whether treatment is intended for disease control or as part of a transplant strategy
The center reviews imaging and treatment history before scheduling
Charité requests the most recent CT or MRI imaging together with the disease course and previous treatments before confirming whether the key requirements for TACE appear to be met. International patients should send actual DICOM imaging whenever the hospital provides a secure route for upload.
TACE may be repeated rather than delivered once
The number and timing of procedures depend on response, liver reserve and the distribution of viable tumor. Charité states that embolization is commonly repeated after several weeks and later reassessed with CT or MRI before deciding whether another TACE or a different treatment should follow.
Conventional TACE and drug-eluting-bead TACE are not identical
Centers may use different embolic materials and chemotherapy-delivery strategies. A hospital recommendation should specify the technique being proposed rather than simply using the label TACE. The choice can affect procedural planning, materials, post-procedure symptoms and cost.
Expect short-term post-embolization symptoms and less common serious risks
Fever, fatigue, nausea and upper-abdominal pain can occur after TACE. Less common but clinically important risks include bleeding or vascular injury from catheterization, infection, non-target embolization, bile-duct or gallbladder injury and worsening liver function. Risk depends heavily on baseline liver reserve and the liver volume treated.
Plan the whole episode, including reassessment
Charité describes inpatient treatment lasting several days and follow-up imaging after the procedure. International patients should clarify admission length, when they can fly, which blood tests are needed after discharge, when CT/MRI reassessment should occur and whether a second session is already anticipated.
Official sources
Sources last checked 2026-09-07.